Switching from ergot to nonergot dopamine agonists in Parkinson's disease: a clinical series and five-drug dose conversion table

Movement Disorders : Official Journal of the Movement Disorder Society
Katherine GrossetDonald Grosset

Abstract

Of 99 patients on ergot-derived dopamine agonists informed about possible long-term side effects, switching to a nonergot was undertaken in 88 (89%). There were adverse events in 26%. After 11 months, 82% were on their switch agonist and 93% were on any agonist. Switching dopamine agonists is feasible in this population.

References

Aug 1, 1989·Neurology·C G GoetzH L Klawans
Jun 1, 1995·Clinical Neuropharmacology·F J Jiménez-JiménezF Gutiérrez
Sep 1, 1996·Movement Disorders : Official Journal of the Movement Disorder Society·G GeminianiT Caraceni
Jan 14, 1999·Journal of Neurology, Neurosurgery, and Psychiatry·S ShaunakD J Dick
Aug 19, 1999·The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques·D E HobsonW R Martin
Oct 18, 2000·JAMA : the Journal of the American Medical Association·UNKNOWN Parkinson Study Group
Mar 23, 2001·Journal of Neural Transmission·P A HannaJ Jankovic
Mar 23, 2002·Neurology·Jean P Hubble
Dec 14, 2002·Mayo Clinic Proceedings·Allison M PritchettRaul E Espinosa

❮ Previous
Next ❯

Citations

Sep 27, 2006·Neurotoxicity Research·Keith ChiassonMaria-Grazia Martinoli
Apr 3, 2007·Journal of Neurology·Günes KiziltanEthem Erginöz
Feb 2, 2010·Journal of Neurology·Hisayoshi OkaSoichiro Mochio
Mar 31, 2010·Journal of Neurology·Diana Maria Elena TortaGiuliano Geminiani
Oct 16, 2012·Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·Carmine VitaleGiuseppe Sorrentino
Aug 21, 2008·Neurocritical Care·Edward J NewmanPeter G E Kennedy
Mar 20, 2012·Acta neurologica Belgica·Marina SvetelVladimir Kostić
Nov 10, 2010·Brain : a Journal of Neurology·Maria C Rodriguez-OrozJose A Obeso
May 7, 2010·The Neurologist·Gülay KenangilEthem Erginöz
Feb 28, 2008·Clinical Neuropharmacology·Gurutz Linazasoro, UNKNOWN Spanish Dopamine Agonists Study Group
Oct 14, 2006·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·M HorstinkUNKNOWN Movement Disorder Society-European Section
Jul 22, 2008·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·J KulisevskyM Martínez-Corral
Mar 1, 2012·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·R González-RedondoM C Rodríguez-Oroz
Jan 3, 2013·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·J J FerreiraW H Oertel
Dec 5, 2012·Dementia and Geriatric Cognitive Disorders·Javier PagonabarragaJaime Kulisevsky
Mar 29, 2014·Revue neurologique·P Cesaro, L Defebvre
Jun 22, 2014·Brain : a Journal of Neurology·Rafael González-RedondoMaría C Rodríguez-Oroz
Apr 21, 2012·Clinical Neurology and Neurosurgery·Yasuhiko BabaTatsuo Yamada
Dec 25, 2015·Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·Valeria AgostiGiuseppe Sorrentino
Nov 3, 2012·International Journal of Alzheimer's Disease·Inga Liepelt-ScarfoneDaniela Berg
Aug 21, 2013·Neuropsychologia·Madeleine E SharpJason J S Barton
Sep 16, 2005·Expert Review of Neurotherapeutics·J Carsten Möller, Wolfgang H Oertel
Apr 3, 2008·Movement Disorders : Official Journal of the Movement Disorder Society·Javier PagonabarragaAlexandre Gironell
Apr 10, 2008·Movement Disorders : Official Journal of the Movement Disorder Society·Kazuo YamashiroYoshikuni Mizuno
Jan 31, 2008·The Journal of International Medical Research·H TakahashiUNKNOWN Pramipexole Switching Study (PraSS) Group
Mar 9, 2012·Stereotactic and Functional Neurosurgery·Elli MarkakiConstantine Constantoyannis
May 14, 2011·Movement Disorders : Official Journal of the Movement Disorder Society·Maria MilenkovaThomas F Münte
Aug 25, 2018·Psychogeriatrics : the Official Journal of the Japanese Psychogeriatric Society·Bilge DoganLevent Sevincok
Nov 4, 2006·Movement Disorders : Official Journal of the Movement Disorder Society·Roberto CiliaAngelo Antonini
May 31, 2007·Movement Disorders : Official Journal of the Movement Disorder Society·Javier PagonabarragaJaime Kulisevsky
Jul 31, 2007·Movement Disorders : Official Journal of the Movement Disorder Society·Angelo AntoniniGianni Pezzoli
Sep 22, 2009·Movement Disorders : Official Journal of the Movement Disorder Society·Kelly E Lyons, Rajesh Pahwa
Oct 21, 2010·Movement Disorders : Official Journal of the Movement Disorder Society·Gisela LlebariaJaime Kulisevsky
Oct 27, 2010·Movement Disorders : Official Journal of the Movement Disorder Society·Daniela FrosiniRoberto Ceravolo
Feb 10, 2006·Expert Review of Neurotherapeutics·Ubaldo Bonuccelli, Nicola Pavese
Jun 1, 2019·Expert Review of Neurotherapeutics·Carmine VitaleGabriella Santangelo
Nov 12, 2010·Movement Disorders : Official Journal of the Movement Disorder Society·Claire L TomlinsonCarl E Clarke
Nov 18, 2014·Acta Neurologica Scandinavica·M NitkowskaA Friedman

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.